PMID- 34963410
OWN - NLM
STAT- MEDLINE
DCOM- 20220525
LR  - 20220622
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 63
IP  - 5
DP  - 2022 May
TI  - Neutrophil decline rate following autologous transplant for lymphoma is a 
      predictor of patients' outcome.
PG  - 1144-1151
LID - 10.1080/10428194.2021.2018580 [doi]
AB  - Neutropenia postchemotherapy is associated with favorable outcomes, which was 
      attributed to optimal dosing. However, little is known about the neutrophil 
      decline rate as a predictor of cancer outcomes, which may reflect a dynamic 
      marker of chemosensitivity. We assessed the association between the neutrophil 
      decline rate and disease outcomes in a known cohort of 212 lymphoma patients, 
      treated with thiotepa, etoposide, cyclophosphamide, cytarabine, and melphalan 
      (TECAM) conditioning followed by autologous transplant in our center between 2000 
      and 2013. Slower neutrophil decline rate was correlated with worse overall 
      survival, mediated not by shorter time to progression (TTP), but rather by worse 
      survival post-progression, possibly pointing to chemosensitivity at each line of 
      therapy as the responsible mechanism. The effect was seen across histologies and 
      was independent of stronger predictors of outcome like performance status (PS) 
      and response before transplant. Prospective research is needed to confirm our 
      results and expand their validity to other clinical scenarios.
FAU - Lebel, Eyal
AU  - Lebel E
AUID- ORCID: 0000-0001-5215-7278
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, 
      Israel.
FAU - Vainstein, Vladimir
AU  - Vainstein V
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, 
      Israel.
FAU - Ashkenazi, Maayan
AU  - Ashkenazi M
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, 
      Israel.
FAU - Zimran, Eran
AU  - Zimran E
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew 
      University Medical Center, Jerusalem, Israel.
FAU - Stepensky, Polina
AU  - Stepensky P
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew 
      University Medical Center, Jerusalem, Israel.
FAU - Grisariu, Sigal
AU  - Grisariu S
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew 
      University Medical Center, Jerusalem, Israel.
FAU - Avni, Batia
AU  - Avni B
AD  - Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
AD  - Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah-Hebrew 
      University Medical Center, Jerusalem, Israel.
LA  - eng
PT  - Journal Article
DEP - 20211229
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 04079A1RDZ (Cytarabine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Autografts
MH  - Cytarabine
MH  - Etoposide/adverse effects
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - *Hodgkin Disease/pathology
MH  - Humans
MH  - *Lymphoma/drug therapy/therapy
MH  - *Lymphoma, Non-Hodgkin/pathology
MH  - Melphalan/adverse effects
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Neutrophils/pathology
MH  - Prospective Studies
MH  - Transplantation Conditioning/methods
MH  - Transplantation, Autologous/methods
OTO - NOTNLM
OT  - kinetics
OT  - Autologous transplant
OT  - lymphoma
OT  - neutrophils
EDAT- 2021/12/30 06:00
MHDA- 2022/05/26 06:00
CRDT- 2021/12/29 05:22
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2022/05/26 06:00 [medline]
PHST- 2021/12/29 05:22 [entrez]
AID - 10.1080/10428194.2021.2018580 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2022 May;63(5):1144-1151. doi: 10.1080/10428194.2021.2018580. Epub 
      2021 Dec 29.